Sympathetic
Logistic model
Neurodegenerative disease
Quantitation
Sympathetic imaging
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
13 Jun 2024
13 Jun 2024
Historique:
received:
19
02
2024
accepted:
31
05
2024
medline:
13
6
2024
pubmed:
13
6
2024
entrez:
13
6
2024
Statut:
aheadofprint
Résumé
We aimed to establish a practical diagnostic index for Lewy body diseases (LBD), such as Parkinson's disease and dementia, with Lewy bodies in outpatient settings and criteria for exempting patients from late imaging. We acquired early and late Early or late SMILe indexes using a single H/M ratio variable discriminated LBD from non-LBD. The AUC values for early and late SMILe indexes were 0.880 and 0.894 (p < 0.0001 for both), identical to those for early and late H/M ratios. The sensitivity and the specificity of early SMILe indexes with a 0.5 threshold were 76% and 90%, achieving accuracy of accuracy 86%. Similarly, the late SMILe index demonstrated a sensitivity of 76% and specificity of 87%, with an accuracy of 84%. Early SMILe indexes < 0.3 or > 0.7 (representing 84% patients) indicated a diagnosis without a late MIBG study. The
Identifiants
pubmed: 38869809
doi: 10.1007/s12149-024-01950-4
pii: 10.1007/s12149-024-01950-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 23K07203
Informations de copyright
© 2024. The Author(s).
Références
Yoshinaga K. Current clinical practice of nuclear cardiology in Japan. Annals of Nuclear Cardiology. 2016;2:50–2.
doi: 10.17996/ANC.02.01.50
JCS Joint Working Group. Guidelines for clinical use of cardiac nuclear medicine (JCS 2010)-digest version. Circ J. 2012;76:761–7.
doi: 10.1253/circj.CJ-88-0019
Hakusui S, Yasuda T, Yanagi T, Tohyama J, Hasegawa Y, Koike Y, et al. A radiological analysis of heart sympathetic functions with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst. 1994;49:81–4.
doi: 10.1016/0165-1838(94)90023-X
pubmed: 7963268
Yoshita M, Arai H, Arai H, Arai T, Asada T, Fujishiro H, et al. Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PLoS ONE. 2015;10: e0120540.
doi: 10.1371/journal.pone.0120540
pubmed: 25793585
pmcid: 4368705
Kashihara K, Ohno M, Kawada S, Okumura Y. Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson’s disease and dementia with Lewy bodies. J Nucl Med. 2006;47:1099–101.
pubmed: 16818943
Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K, et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson’s disease. Brain Pathol. 2007;17:24–30.
doi: 10.1111/j.1750-3639.2006.00032.x
pubmed: 17493034
pmcid: 8095543
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–601.
doi: 10.1002/mds.26424
pubmed: 26474316
Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, et al. Movement disorder society criteria for clinically established early Parkinson’s disease. Mov Disord. 2018;33:1643–6.
doi: 10.1002/mds.27431
pubmed: 30145841
Yoshita M, Taki J, Yamada M. A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer’s-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2001;71:583–8.
doi: 10.1136/jnnp.71.5.583
pubmed: 11606666
pmcid: 1737586
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–72.
doi: 10.1212/01.wnl.0000187889.17253.b1
pubmed: 16237129
Treglia G, Cason E. Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with Lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging. 2012;22:111–7.
doi: 10.1111/j.1552-6569.2010.00532.x
pubmed: 21091814
Komatsu J, Samuraki M, Nakajima K, Arai H, Arai H, Arai T, et al. 123I-MIBG myocardial scintigraphy for the diagnosis of DLB: a multicentre 3-year follow-up study. J Neurol Neurosurg Psychiatry. 2018;89:1167–73.
doi: 10.1136/jnnp-2017-317398
pubmed: 29853532
Parkison Disease Practice Guidelines 2018. Japanese Society of Neurology. 2018. https://www.neurology-jp.org/guidelinem/pdgl/parkinson_2018_24.pdf (in Japanese). Accessed 1 Feb 2024.
Orimo S, Yogo M, Nakamura T, Suzuki M, Watanabe H. (123)I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in alpha-synucleinopathies. Ageing Res Rev. 2016;30:122–33.
doi: 10.1016/j.arr.2016.01.001
pubmed: 26835846
McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89:88–100.
doi: 10.1212/WNL.0000000000004058
pubmed: 28592453
pmcid: 5496518
Yamada M, Komatsu J, Nakamura K, Sakai K, Samuraki-Yokohama M, Nakajima K, et al. Diagnostic criteria for dementia with Lewy bodies: updates and future directions. J Mov Disord. 2020;13:1–10.
doi: 10.14802/jmd.19052
pubmed: 31694357
Nakajima K, Yoshita M, Matsuo S, Taki J, Kinuya S. Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Med Mol Imaging. 2008;52:378–87.
pubmed: 19088692
Nakajima K, Okuda K, Matsuo S, Yoshita M, Taki J, Yamada M, et al. Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging. 2012;39:113–9.
doi: 10.1007/s00259-011-1963-1
pubmed: 22009380
Nakajima K, Okuda K, Yoshimura M, Matsuo S, Wakabayashi H, Imanishi Y, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol. 2014;21:970–8.
doi: 10.1007/s12350-014-9916-2
pubmed: 24942608
pmcid: 4167440
Okuda K, Nakajima K, Kitamura C, Kirihara Y, Hashimoto M, Kinuya S. Calibrated scintigraphic imaging procedures improve quantitative assessment of the cardiac sympathetic nerve activity. Sci Rep. 2020;10:21834.
doi: 10.1038/s41598-020-78917-8
pubmed: 33318541
pmcid: 7736873
Verschure DO, Poel E, Nakajima K, Okuda K, van Eck-Smit BLF, Somsen GA, et al. A European myocardial 123I-mIBG cross-calibration phantom study. J Nucl Cardiol. 2018;25:1191–7.
doi: 10.1007/s12350-017-0782-6
pubmed: 28120154
Okuda K, Nakajima K, Hung G, Wu H, Verschure D, Verberine H, et al. Comparison of Taiwanese and European calibration factors for heart-to-mediastinum ratio in multicenter 123I-mIBG phantom studies. Ann Nucl Cardiol. 2023;9:54–60.
doi: 10.17996/anc.23-00006
pubmed: 38058572
pmcid: 10696153
Schirinzi T, Di Lazzaro G, Sancesario GM, Summa S, Petrucci S, Colona VL, et al. Young-onset and late-onset Parkinson’s disease exhibit a different profile of fluid biomarkers and clinical features. Neurobiol Aging. 2020;90:119–24.
doi: 10.1016/j.neurobiolaging.2020.02.012
pubmed: 32169356
Pitton Rissardo J, Fornari Caprara AL. Cardiac 123I-Metaiodobenzylguanidine (MIBG) scintigraphy in Parkinson’s disease: a comprehensive review. Brain Sci. 2023;13:1471.
doi: 10.3390/brainsci13101471
pubmed: 37891838
pmcid: 10605004
Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson’s disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2012;18:494–500.
doi: 10.1016/j.parkreldis.2012.01.009
pubmed: 22321865
Okuda K, Nakajima K, Hosoya T, Ishikawa T, Konishi T, Matsubara K, et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac Iodine-123 MIBG imaging. J Nucl Cardiol. 2011;18:82–9.
doi: 10.1007/s12350-010-9313-4
pubmed: 21104360
Nakajima K, Okuda K, Matsuo S, Wakabayashi H, Kinuya S. Is 123I-metaiodobenzylguanidine heart-to-mediastinum ratio dependent on age? from Japanese Society of Nuclear Medicine normal database. Ann Nucl Med. 2018;32:175–81.
doi: 10.1007/s12149-018-1231-6
pubmed: 29333564
pmcid: 5852176
Flotats A, Carrio I, Agostini D, Le Guludec D, Marcassa C, Schafers M, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802–12.
doi: 10.1007/s00259-010-1491-4
pubmed: 20577740
Tsuchimochi S, Tamaki N, Tadamura E, Kawamoto M, Fujita T, Yonekura Y, et al. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging. J Nucl Med. 1995;36:969–74.
pubmed: 7769454
Roberts G, Kane JPM, Lloyd J, Firbank M, Donaghy PC, Petrides GS, et al. Can early phase cardiac [123I]-mIBG images be used to diagnose Lewy body disease? Nucl Med Commun. 2022;43:770–7.
doi: 10.1097/MNM.0000000000001581
pubmed: 35603421
pmcid: 9177152
Verberne HJ, Feenstra C, de Jong WM, Somsen GA, van Eck-Smit BL, Busemann SE. Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging. 2005;32:1100–7.
doi: 10.1007/s00259-005-1810-3
pubmed: 15902438
Verschure DO, de Wit TC, Bongers V, Hagen PJ, Sonneck-Koenne C, D’Aron J, et al. 123I-MIBG heart-to-mediastinum ratio is influenced by high-energy photon penetration of collimator septa from liver and lung activity. Nucl Med Commun. 2015;36:279–85.
doi: 10.1097/MNM.0000000000000238
pubmed: 25415845
Roberts G, Lloyd JJ, Kane JPM, Durcan R, Lawley S, Howe K, et al. Cardiac 123I-MIBG normal uptake values are population-specific: Results from a cohort of controls over 60 years of age. J Nucl Cardiol. 2021;28:1692–701.
doi: 10.1007/s12350-019-01887-6
pubmed: 31529384
Jacobson AF, Chen J, Verdes L, Folks RD, Manatunga DN, Garcia EV. Impact of age on myocardial uptake of 123I-mIBG in older adult subjects without coronary heart disease. J Nucl Cardiol. 2013;20:406–14.
doi: 10.1007/s12350-013-9701-7
pubmed: 23483457
Nakajima K, Okuda K, Komatsu J. What does diagnostic threshold mean? Deterministic and probabilistic considerations. J Nucl Cardiol. 2021;28:1702–6.
doi: 10.1007/s12350-019-01899-2
pubmed: 31549288
Sakamoto F, Shiraishi S, Tsuda N, Ogasawara K, Yoshida M, Yuki H, et al. 123I-MIBG myocardial scintigraphy for the evaluation of Lewy body disease: are delayed images essential? Is visual assessment useful? Br J Radiol. 2016;89:20160144.
doi: 10.1259/bjr.20160144
pubmed: 27222274
pmcid: 5124887
Manabe Y, Inui Y, Toyama H, Kosaka K. 123I-metaiodobenzylguanidine myocardial scintigraphy with early images alone is useful for the differential diagnosis of dementia with Lewy bodies. Psychiatry Res Neuroimaging. 2017;261:75–9.
doi: 10.1016/j.pscychresns.2016.12.011
pubmed: 28152401
Saito S, Nakajima K, Komatsu J, Shibutani T, Wakabayashi H, Mori H, et al. 2024 Absolute quantitation of sympathetic nerve activity using [123I] metaiodobenzylguanidine SPECT-CT in neurology. EJNMMI Rep. 2024;8:15